Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040Newsfile Corp • 11/13/25
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial DiseasesNewsfile Corp • 11/05/25
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027Newsfile Corp • 10/21/25
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027Newsfile Corp • 10/17/25
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth ConferenceNewsfile Corp • 08/11/25
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute MyocarditisNewsfile Corp • 08/06/25
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute MyocarditisNewsfile Corp • 07/22/25
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of ShareholdersNewsfile Corp • 05/29/25
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDTNewsfile Corp • 05/27/25
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisNewsfile Corp • 04/16/25
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceNewsfile Corp • 03/03/25
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failureProactive Investors • 02/20/25
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart FailureNewsfile Corp • 02/20/25
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation CatalystsSeeking Alpha • 02/19/25
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNewsfile Corp • 02/04/25
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent PericarditisGlobeNewsWire • 12/19/24
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapyProactive Investors • 11/18/24
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024Newsfile Corp • 11/18/24